LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T6833

    Triacetyl Aloe-emodin (Impurity A)

    Derivative of aloe-emodin, anthraquinone found ...

    ≥98%
  • C291342

    CHIR-99021

    GSK3 inhibitor.

    ≥98%
  • N1757

    Neostigmine Bromide

    AChE inhibitor.

    ≥92%
  • P2002

    PF-04691502 Dihydrate

    PI3K and mTOR inhibitor.

    ≥98%
  • L8276

    Luteinizing Hormone Releasing Hormone

    Endogenous peptide hormone; GnRH agonist.

    ≥98%
  • M188776

    9-(Methylsulfonyl)nonanyl nitrile

    Synthetic nitrile compound

    ≥98%
  • E9819

    Ezetimibe

    NPC1L1 inhibitor.

    ≥99%
  • B1746

    Belinostat

    HDAC inhibitor.

    ≥98%
  • L9874

    L-(+)-Lysine Monohydrate

    Non-endogenous essential amino acid found in me...

    ≥95%
  • T5060

    TMP-269

    HDAC inhibitor.

    ≥98%
  • M1679

    Methysticin

    Kavalactone originally found in Piper methystic...

    ≥98%
  • D1693

    Dexamethasone

    Glucocorticoid agonist.

    ≥99%
  • V0269

    Vardenafil Dihydrochloride

    PDE5 inhibitor.

    ≥99%
  • R0348

    Ramelteon

    Melatonin analog; MT1/2 agonist.

    ≥99%
  • P004080

    PAC-1

    Zinc chelator

    ≥98%
  • D0010

    3H-1,2-Dithiole-3-thione

    Induces activation of Nrf2; inhibits apoptosis ...

    ≥98%
  • C9614

    Cyclosporin H

    Cyclosporin metabolite; formyl peptide inhibito...

    ≥96%
  • B4796

    BLZ-945

    CSF-1R Inhibitor.

    ≥95%
  • H1893

    Hexarelin

    Synthetic ghrelin analog; ghrelin agonist.

    ≥95%
  • G733400

    GSK-2578215A

    Selective inhibitor of LRRK2.

    ≥98%